Sanofi: finalises acquisition of Bioverativ
(CercleFinance.com) - Sanofi has announced its finalisation of the acquisition of Bioverativ Inc.
, for which it has paid 105 dollars in cash per share.
Bioverativ will continue to operate under its own name, becoming an indirect subsidiary that is fully owned by Sanofi.
Sanofi's CEO Olivier Brandicourt said that the acquisition of Bioverativ provides our group with a strong position in the growing market of Hemophilia and expands our presence in the segment of specialty medicines.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
, for which it has paid 105 dollars in cash per share.
Bioverativ will continue to operate under its own name, becoming an indirect subsidiary that is fully owned by Sanofi.
Sanofi's CEO Olivier Brandicourt said that the acquisition of Bioverativ provides our group with a strong position in the growing market of Hemophilia and expands our presence in the segment of specialty medicines.
Copyright (c) 2018 CercleFinance.com. All rights reserved.